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Abstract 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with 
immunosuppressive functions; these cells play a key role in infection, immunization, chronic inflammation, and 
cancer. Recent studies have reported that immunosuppression plays an important role in the healing process of 
tissues and that Treg play an important role in fracture healing. MDSCs suppress active T cell proliferation and 
reduce the severity of arthritis in mice and humans. Together, these findings suggest that MDSCs play a role in 
bone biotransformation. In the present study, we examined the role of MDSCs in the bone healing process by 
creating a bone injury at the tibial epiphysis in mice. MDSCs were identified by CD11b and GR1 
immunohistochemistry and their role in new bone formation was observed by detection of Runx2 and 
osteocalcin expression. Significant numbers of MDSCs were observed in transitional areas from the reactionary 
to repair stages. Interestingly, MDSCs exhibited Runx2 and osteocalcin expression in the transitional area but 
not in the reactionary area. And at the same area, cllagene-1 and ALP expression level increased in osteoblast 
progenitor cells. These data is suggesting that MDSCs emerge to suppress inflammation and support new bone 
formation. Here, we report, for the first time (to our knowledge), the role of MDSCs in the initiation of bone 
formation. MDSC appeared at the transition from inflammation to bone making and regulates bone healing by 
suppressing inflammation. 
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Introduction 
Myeloid-derived suppressor cells (MDSCs) are a 
heterogeneous population of immature myeloid cells 
that play a distinct role in immunosuppression. There 
are two major subpopulations of MDSCs, monocytic 
MDSCs (M-MDSCs) and polymorphonuclear or 
granulocytic MDSCs (PMN-MDSCs); phenotypically 
and morphologically, these subpopulations are akin 
to monocytes and neutrophils, respectively [1,2]. 
Recently, fibrocytic MDSCs (F-MDSCs) were 
characterized in humans as circulating fibrocytes with 
T cell-mediated immune suppressive functions [3]. In 
mice, total MDSCs have been characterized as GR1- 
and CD11b-expressing cells. MDSCs have been 
described primarily in the bone marrow, peripheral 
blood, spleen, liver, lung, or tumors of various organs. 
MDSCs are not detectable under physiological 
conditions and emerge only in pathological 
conditions such as infection, immunization, chronic 
inflammation, and cancer [4-8]. MDSCs are known for 
their role in immune suppression in cancer, and for 
their functions in facilitating tumor development and 
metastasis [9-13]. MDSCs also function as osteoclast 
progenitors and contribute to cancer-induced 
osteolysis [14,15]. MDSCs play a crucial role in 
regulating mouse collagen-induced arthritis and 
rheumatoid arthritis by inhibiting the 
proinflammatory immune response [16]. However, 










The healing process of bone is a physiologically 
complicated process involving multicellular 
interactions that comprise three major phases: 
reaction, repair, and remodeling [17]. Transition from 
reaction to repair is critical. Initial inflammation is 
important for the successful healing process. 
However, excess inflammation results in failure of the 
healing process [18,19]. Counterbalancing of 
inflammation is indispensable for bone healing. 
Notably, the balance of effector T cell and regulatory T 
cell (Treg) has been reported to play a key role in bone 
healing [20]. Elevation of the number of Treg cells 
improves bone healing. Moreover, in human and 
mouse, intermittent parathyroid hormone-induced 
Treg cell proliferation has been shown to provide 
promising results in osteoblast proliferation and bone 
formation [21]. MDSCs impart immunosuppressive 
functions by stimulating the proliferation of Treg 
cells. Thus, we speculated that MDSCs might play a 
role in the bone healing process. In the present study, 
we created bone injury in mouse and investigated the 
emergence of MDSCs during the bone healing 
process. Our results demonstrated that MDSCs occur 
only transiently in the bone healing process, but these 
cells have the potential to play a role in bone healing 
by emerging in the transitional period and initiating 
the repair phase. 
Materials and Methods 
Experimental animals 
A total of 12 female mice (C57BL/6) were 
purchased from Charles River Laboratories Japan, Inc. 
Mice were housed under pathogen-free conditions. 
This research was approved by the Animal 
Experiment Control Committee of Okayama 
University, Graduate School of Medicine, Dentistry 
and Pharmaceutical Sciences (Approval No. 
05-006-099). All mouse experiments were conducted 
in accordance with procedures approved by the 
Okayama University “Guidelines for the Care and 
Use of Laboratory Animals”. 
Bone Injury model 
A skeletal injury model was generated as 
described by Kim et al. [22]. We used a dental 
laboratory MARATHON Micromotor N3 35000 RPM 
instrument equipped with a BUSH steel bar (round, 
1.0 mm, Catalog 4290008) for generating drill holes. 
All procedures were performed under general 
anesthesia. Using a 1.0-mm drill bit, a 
1.0-mm-diameter hole was created in the center of the 
tibial bone cortex, approximately 5 mm from the 
epiphysis. Mice of separate groups (n=3 each) were 
euthanized at post-surgical day (PD) 3, 7, 14, or 28, 
and tibias were collected (Figure 1). 
Histological examination 
Collected mouse tibias were fixed in 4% 
paraformaldehyde for 12 h and decalcified in 10% 
EDTA at 4 °C for 14 days. Samples then were 
sequentially dehydrated in 70% ethanol and 
embedded in paraffin. Serial sections (5-μm 
thicknesses) were prepared. Sections were subjected 
to hematoxylin and eosin (HE) staining using 
standard methods, and to immunohistochemistry 
(IHC) and double IHC staining as described below. 
Immunohistochemistry 
Paraffin-embedded tissue sections were 
deparaffinized in a series of xylene solutions for 15 
min, rehydrated in graded ethanol solutions, and 
incubated in a solution of 3% hydrogen peroxide in 
methanol for 30 min to quench endogenous 
peroxidases. Antigen retrieval then was 
performed, with the technique employed 
depending on the respective antibody. 
Details of the primary antibodies used and 
the antigen retrieval methods are shown in 
Table 1. Following antigen retrieval, sections 
were treated with 10% normal serum (Vector 
Lab, Burlingame, CA) for 30 min at room 
temperature in a humidified chamber, 
followed by incubation with primary 
antibodies at 4 °C overnight. Secondary 
biotinylated antibody was applied using the 
avidin–biotin complex method (Vector Lab, 
Burlingame, CA). Color development was 
performed with 3, 3’-diaminobenzidine 
(DAB) (Histofine DAB substrate; Nichirei, 
Tokyo, Japan) and counterstained with 
Mayer’s hematoxylin. Staining results were 
evaluated using an optical microscope. 
 
 
Figure 1. Bone injury model. (A) Demonstration of experimental procedure. Bone injuries were 
created in 11-week old C57BL/6 wild-type mice. Mice of separate groups (n=3 each) were euthanized 
at post-surgical day (PD) 3, 7, 14, or 28; the tibias were recovered at necropsy and subjected to 
histopathological assessment. (B) Illustration of the bone injury site. A bone injury consisting of a 
1-mm-diameter hole was generated at the center of the tibial bone cortex, approximately 5 mm from 
the epiphysis. 






Figure 2. Histological evaluation of bone healing process. To detect the phases of the bone healing process, a bone injury was created in the mouse tibia, and hematoxylin and 
eosin staining was performed at PD 3, 7, 14, and 28 (n = 3 mice for time point). (A) Injury site is demarcated by the solid line. (B) Early reaction to the injury (hematoma formation, 
necrotic tissue, and inflammatory cell infiltration) was observed at PD 3. (C, D) At PD 7, the injury site showed reaction and repair within a transitional area: above the transitional 
area (surrounded by the dotted line), the tissue was in the early reaction phase; below, the tissue is in the repair phase. Remaining necrotic tissue, granulation tissue, and new 
bone formation also were observed. (E) At PD 14, the injury site had entered the repair phase. (F) At PD 28, the injury site was undergoing remodeling, and showed mature bony 
tissue formation and bone marrow restoration. Nt: necrotic tissue, Gt: granulation tissue, NB: new bone, MB: mature bone. Scale bars: A, 200 µm; B, C, D, E, and F, 100 µm. 
Lower-case letters b-f indicate regions in micrographs in A that are provided (in expanded form) in the corresponding upper-case panels B to F.  
 






Antigen retrieval Dilution Supplier 
GR1 Rat 0.1% Trypsin at 37 °C, 5 
min 
1:200 Biolegend 
CD11b Rabbit Microwave heating in 
0.01 mol/L citrate buffer 
(pH 6.0) at 100 °C, 1 min 
1:500 abcam 
Runx2 Rabbit Microwave heating in 
0.01 mol/L EDTA buffer 
(pH 9.0) at 100 °C, 1 min 
1:1000 abcam 
Osteocalcin Rabbit Microwave heating in 
0.01 mol/L citrate buffer 
(pH 6.0) at 100 °C, 1 min 
1:1000 abcam 
Collagen 1 Rabbit Microwave heating in 
0.01 mol/L citrate buffer 
(pH 6.0) at 100 °C, 1 min 
1:500 Cell 
Signaling 
ALP Rabbit Microwave heating in 
0.01 mol/L citrate buffer 
(pH 6.0) at 100 °C, 1 min 
1:200 TAKARA 
GR1 and CD11b double IHC staining. 
 
 
Double IHC staining was performed using 
anti-GR1 and anti-CD11b antibodies. Binding by the 
first primary antibody (anti-GR1) was detected as 
described above and color development was 
performed using DAB liquid. In a second round of 
staining, sections were further stained to detect a 
different antigen by incubation with a second primary 
antibody (anti-CD11b) for 1 h, followed by its 
corresponding secondary antibody (Vector Lab, 
Burlingame, CA). For the second-round staining, 
color development was performed using 
3-amino-9-ethyl carbazole (AEC) (Dako Cytomation). 
Counterstaining then was performed with Mayer’s 
hematoxylin. 
Statistical analysis 
The number of positively labeled cells was 
counted manually in fields at 400× (n = 3 fields). Data 
are presented as mean ± standard deviation (s.d.) 
where appropriate, and were analyzed using 
two-tailed non-paired Student’s t-tests by using excel 
software. Differences were considered significant at P 
< 0.05. 
Results 
Bone injury models 
To evaluate the bone healing process, we first 
created a mouse model of bone injury. The injury was 
generated in the tibias of female C57BL/6 mice, and 
sequential evaluations were performed at PD 3, 7, 14, 
and 28. 
As a first step, we identified the stages of the 
bone healing process by HE staining of samples of 
injured tibias recovered at PD 3, 7, 14, and 28. All 
stages of the healing process (reaction (early and late), 
repair, and remodeling) were observed. At PD 3, early 
reaction to the injury, such as hematoma formation 
and necrotic bone tissue, was observed and there was 
infiltration of some inflammatory cells into the injury 
site (Figure 2A). The infiltrating inflammatory cells 




consisted of neutrophils and macrophages (Figure 
2B). At PD 7, the tissue at the injury site not only 
showed a reaction (early and late), but also entered 
the repair phase of the healing process (Figure 2A). 
Notably, a portion of the blood clot and necrotic bone 
remained immediately beneath the thickening 
periosteum, and late reaction to injury (e.g., 
granulation tissue with newly formed blood vessels) 
was observed. The inflammatory cell infiltration 
persisted (Figure 2C). At the base of the injury, tissue 
was undergoing the repair process and showed the 
formation of bony callus (Figure 2D). The newly 
formed bony callus was surrounded by granulation 
tissue, indicating that the granulation area (late 
reaction) comprised the transitional area from the 
reaction to repair stages. At PD 14, an immature bony 
structure fully occupied the injury site and intact 
periosteum covered the bony injury (Figure 2A). 
Inflammation had subsided and granulation tissue 
was in close proximity to the newly formed bony 
tissue (Figure 2E). At PD 28, the bony continuity and 
marrow space were restored. Mineralized osteoid 
with osteocytes was observed (Figure 2A, F). 
Tissue at PD 7 shows significant accumulation 
of GR1- and CD11b-positive cells 
Inflammation is a naturally occurring body 
defense mechanism and is essential for the healing 
process. However, the balance of inflammation also is 
important for entering the repair stage. This fact made 
us interested in the role of MDSCs in the healing 
process. Hence, we assessed, by IHC and double IHC 
staining, the presence of GR1- and CD11b-positive 
cells at the injury site and compared the levels of these 
positively staining cells during the phases of the 
healing process. Rounded, dendritic, and spindle- 
shaped cells were positive for GR1 and CD11b 
staining. Almost all of the GR1- and CD11b-double- 
positive cells were round in shape, but not 
polymorphonuclear. At PD 3, GR1- and CD11b- single 
stained cells were widely distributed throughout the 
injury site (Figure 3A, B), although double-stained 
cells were seen only rarely (Figure 3C, D, E). At PD 7, 
GR1-positive cells aggregated around the repaired 
bone and blood vessels in the transitional area 
(surrounded by the dotted line) (Figure 3F). However, 
CD11b-positive cells were more likely to occur in the 
reactionary area than in the transitional area 
(surrounded by the dotted line) (Figure 3G). With IHC 
double staining, cells positive for double staining 
were seen in the transitional area, proximal to the 
newly formed bony structure and blood vessels 
(Figure 3H, I, J). 
At PD 14, the number of GR1- and 
CD11b-positive cells decreased dramatically (Figure 
4A, B). Negligible numbers of double-stained cells 
were seen (Figure 4C, D, E). At PD 28, some of the 
restored bone marrow cells exhibiting staining for 
GR1 or CD11b (Figure 4F, G). IHC double staining 
showed that some of the restored bone marrow cells 
expressed both markers ((Figure 4H, I, J). 
Number of GR1+CD11b+ MDSCs increases in 
the transitional area with the shift from 
reaction to repair phase 
The above data demonstrated that GR1 and 
CD11b expression and localization differed among 
the various phases of the healing process. The distinct 
expression profile of MDSCs led us to focus on events 
at PD 7, a time when we can observe the transition 
from the reaction to repair phase. Therefore, we 
performed statistical analysis to assess MDSC 
emergence at PD 7. First, we 
divided the healing site into three 
regions: early reaction, transition, 
and repair areas (Figure 5A). Three 
images per sample were used for 
data analysis. The double-stained 
cells were counted manually and 
numbers compared among the 
three areas. We found that the 
number of double-stained cells 
was significantly higher in the 
transitional area than either of the 
other two areas (Figure 5B). This 
finding indicated that the role of 
MDSCs in the healing process is 
short-lived, suggesting that this 
cell type may play a role in 
establishing an immune balance to 
facilitate bone repair. 
 
 
Figure 3. IHC and double IHC characterization and localization of Gr1 and CD11b expression in bony injury site. 
Gr1-positive cells were rounded and spindle-shaped. At PD3, Gr1- and CD11b-positive cells were widely 
distributed at the injury site (A, B). IHC double staining revealed the presence of low numbers of double-positive cells 
(C, D, E). At PD7, however, Gr1 expression localized specifically in the transition area (surrounded by the dotted 
line) (F). CD11b-positive cells were still present in the injury site, particularly at the inflammatory area (above the 
area surrounded by the dotted line) (G). Interestingly, double-positive cells (arrowheads) were gathered in the 
granulation area proximal to the repair area (H, I, J). Scale bars: A, B, C, F, G, and H, 200 µm; D, E, I, and J, 100 µm. 






Figure 4. IHC and double IHC characterization and localization of Gr1 and CD11b expression in bony injury site. At PD14, the numbers of cells exhibiting staining for Gr1 and 
CD11b, either alone or together, were significantly decreased (A, B, C, D, E). At PD28, the injury site showed complete healing; restored bone marrow cells positive for Gr1 
(F) were seen, along with a small number of CD11b-positive cells (G). Some restored bone marrow cells expressed both markers (H, I, J). Scale bars: A, B, C, F, G, and H, 200 
µm; D, E, I, and J, 100 µm. 
 
Figure 5. Statistical analysis of GR1, CD11b double-positive cells in the process of bone healing. (A) Demonstration of area division on PD 7 sections; the area surrounded by 
a dotted line corresponds to the transition area (green box), which is flanked by the reaction area (above; red box) and the repair area (below; blue box). Scale bar: 200 µm. (B) 
Quantification of GR1-, CD11b double-stained cells in a given field at 400x magnification (n = 3 fields/sample). Statistical significance was assessed using non-paired two-tailed 
Student’s t-tests. Data are presented as mean ± s.d. 
 
MDSCs support bone formation 
Next, to evaluate the relationship of MDSCs to 
new bone formation and inflammation, we analyzed 
osteoblast differentiation using Runx2, a marker of 
osteoblastic differentiation, and osteocalcin, a marker 
of mature osteoblasts (Figure 6A, D). To verify 
osteoblastic differentiation in the transition area, we 
also analyzed expression of collagen-1 and alkaline 
phosphatase (ALP). Interestingly, Runx2 staining was 
observed in the transition area, adjacent to the newly 
formed bone, but not in the inflammatory area (Figure 
6B, C). Osteocalcin-positive cells were observed in the 
periphery of the newly formed bone (Figure 6E, F). 
Expression of collagen-1 and ALP localized to the 
transition area, and cells positive for these markers 
had round or spindle shapes (Figure 6H, I, K, L). 
These results suggested that inflammation impedes 
the differentiation of osteoblasts and MDSCs in the 
transitional area, further indicating that MDSCs might 
play a supporting role in new bone formation. 
Discussion 
Bone healing is a complex and dynamic process 
involving many harmonious and coordinated 
intercellular and molecular interactions [21]. During 
the healing process, the transition from inflammation 
to repair phase is critical. In the bone injury model 
used here, the healing phases demonstrate the point 
of intersection among the various phases: tissues 
obtained at the PD-3, PD-14, and PD-28 time points 
showed the reactionary, repair, and remodeling 
phases, respectively, while tissues obtained at the 
PD-7 time point showed both the reaction and repair 
phases. At PD 7, the injury site exhibited three 
different areas from superficial to deep, 
corresponding to inflammation, granulation tissue, 
and repair areas, respectively. This appearance 
suggested that the middle (granulation) area is a 
transitional area. Hence, we were able to observe the 
transition from inflammation to repair at PD 7. 




The immune system plays a crucial role in 
successful healing of bony injuries [22]. Neutrophils, 
macrophages, and dendritic cells stimulate osteoclast 
formation via the helper T cell (Th 17)-mediated 
RANKL signaling pathway [23-25]. On the other 
hand, Th1 and Th2 T cells inhibit osteoclast formation 
[26]. Moreover, Treg cells inhibit the differentiation 
and function of osteoclasts and suppress 
inflammation [27–29]. In recent years, MDSCs have 
been reported to provide immune suppression by 
inhibiting the proliferation and function of T cells 
while stimulating the proliferation of Treg cells [30]. 
These data suggest that MDSCs potentially contribute 
to bone healing process via immune suppression. 
Notably, in the present study, GR1- and CD11b 
double-stained cells localized in the transition area at 
PD 7. Mature neutrophils and macrophages also 
express GR1 and CD11b [31,32]. However, the cells 
we identified here as MDSCs do not have the 
characteristics of mature neutrophils and 
macrophages. These MDSCs were not observed in the 
inflammatory area, and the number of these cells 
decreased significantly at PD 14 and thereafter. These 
findings suggested that MDSCs accumulate to the 
highest levels during the transition from the 
reactionary to repair phase. 
Our study showed that Runx2, osteocalcin, 
collagen-1, and ALP expression level were elevated in 
cells that localized to the transition area. Runx2 and 
osteocalcin are markers of osteoblasts and osteoblastic 
progenitor cells [35]. Our data indicated that 
osteoblast progenitor cells were localized to the 
transition area, whereupon osteoblast differentiation 
occurred, as demonstrated by the expression of 
collagen-1 and ALP by spindle-shaped or round 
stromal cells [36]. Notably, we observed that the 
localization of GR1- and CD11b double-stained cells 
was closely related to new bone formation (evidenced 
by Runx2 expression). We inferred that MDSCs play a 
role in new bone formation and might be a focal point 
in balancing the connection between inflammation 
and bone repair. 
Conclusions 
Together, the findings of the present 
study are first demonstration (to our 
knowledge) that MDSCs contribute to new 
bone formation during bone healing. MDSCs 
may play a role in bone healing by transiently 
emerging in the transitional period and 
initiating the repair phase. 
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Figure 6. Relation of MDSCs to inflammation and new bone formation. Detection of Runx2, 
osteocalcin, collagen-1, and ALP expression at PD7 (A-L). Inflammatory area showed no 
expression of Runx2, osteocalcin, collagen-1, or ALP (B, E, H, K). Runx2- and 
osteocalcin-expressing cells localized between the area of inflammation and the repair area 
(arrowheads) (C, F). Collagen-1- and ALP-positive spindle-shaped cells localized to the same 
transition area (arrow) (I, L). Scale bars: a and d, 200 µm; b, c, e, and f, 100 µm. 
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